Ilya Pharma: Clinical Trials

1 trial sponsored by Ilya Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Terminated 1

Follow Ilya Pharma: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2, ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2, Placebo - Wound Heal, Wound Healing Disturbance of
Phase 2TerminatedIlya Pharma12022-09-262025-03-05

Conditions studied

Diabetic Foot (1)

Countries

Sweden (1)

Top investigators

Jan Apelqvist, MD/PhD (1)